Cowen and Company restated their buy rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research report report published on Thursday. The brokerage currently has a $151.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on ALNY. Goldman Sachs Group, Inc. (The) raised shares of Alnylam Pharmaceuticals from a neutral rating to a buy rating and upped their target price for the stock from $62.00 to $163.00 in a report on Monday, October 2nd. Jefferies Group LLC set a $102.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Friday, August 25th. B. Riley decreased their target price on shares of Alnylam Pharmaceuticals to $220.00 and set a buy rating on the stock in a report on Wednesday. Barclays PLC upped their target price on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an equal weight rating in a report on Thursday, August 10th. Finally, BMO Capital Markets reaffirmed an outperform rating and set a $99.00 target price (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 6th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have issued a buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of Buy and a consensus price target of $114.57.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up $2.30 during trading on Thursday, reaching $139.98. 1,386,900 shares of the company were exchanged, compared to its average volume of 1,120,946. The company has a debt-to-equity ratio of 0.14, a quick ratio of 8.84 and a current ratio of 9.83. Alnylam Pharmaceuticals has a twelve month low of $35.98 and a twelve month high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business’s revenue was up 24.8% on a year-over-year basis. During the same period last year, the company posted ($1.21) EPS. research analysts expect that Alnylam Pharmaceuticals will post -5.18 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Given “Buy” Rating at Cowen and Company” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-alny-given-buy-rating-at-cowen-and-company/1696760.html.

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,000 shares of the stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $130.00, for a total transaction of $2,600,000.00. Following the completion of the sale, the director now owns 20,000 shares of the company’s stock, valued at approximately $2,600,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the stock in a transaction on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the sale, the executive vice president now directly owns 45,201 shares of the company’s stock, valued at approximately $5,490,113.46. The disclosure for this sale can be found here. Insiders have sold a total of 215,797 shares of company stock valued at $25,035,072 in the last three months. 4.30% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. State of Wisconsin Investment Board boosted its position in Alnylam Pharmaceuticals by 0.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company boosted its position in Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the period. Prudential Financial Inc. boosted its position in Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 200 shares during the period. Utah Retirement Systems lifted its position in shares of Alnylam Pharmaceuticals by 1.5% in the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock worth $1,100,000 after purchasing an additional 200 shares during the period. Finally, Alliancebernstein L.P. lifted its position in shares of Alnylam Pharmaceuticals by 0.8% in the 2nd quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock worth $3,818,000 after purchasing an additional 398 shares during the period. 94.20% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.